01/30/2026
Clinical research is changing—and the industry is demanding greater predictability, transparency, and data integrity than ever before.
Andrew Reina, Chief Revenue Officer, shares why the traditional, relationship‑driven approaches to site selection are no longer enough—and how AI is reshaping feasibility into a more evidence‑driven, consistent, and confident process.
In his new article, Drew explores:
🔹 Why site selection needs a data reset as Sponsors push for trials that start faster and perform more predictably
🔹 How AI can transform feasibility from opinion-based to evidence-based decision-making
🔹 Why predictability is foundational to data quality—and how better alignment between protocol demands and site capabilities can reduce delays and downstream issues
🔹 How Velocity’s integrated network structure turns scale into intelligence, enabling meaningful performance analysis that many individual sites simply can’t support
🔹 How this new approach raises expectations across the network, driving continuous improvement and operational excellence
Velocity’s AI-powered feasibility and site intelligence tool launches its first phase this February—designed to bring more rigor, clarity, and confidence to site selection decisions.
This is more than a new technology. It’s a step toward a more predictable, data-led clinical research ecosystem—one that strengthens Sponsor relationships with transparent, evidence-backed insights.
Read the full article to see how AI can support your next study with greater confidence and consistency: https://velocityclinical.com/why-site-selection-needs-a-data-reset-and-how-ai-can-deliver-it/
